Program
Please note that this meeting will take place as an in-person event in Toronto and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference. Please see the registration page for details.
CME credit is available for in-person attendance for the designated sessions. On-demand presentations are not eligible for CME.
All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.
*-Short talk from proffered abstract
Thursday, September 5
Friday, September 6
- Plenary Session 1: Cancer Predisposition and the Causes of Cancer
- Plenary Session 2: Precision Medicine for Pediatric Cancer: Beyond Sequencing
- Plenary Session 3: Title to be announced
Saturday, September 7
- Plenary Session 4: Circulating DNA and Other Novel Early Relapse Detection Tools
- Plenary Session 5: Pediatric Cancer Disparities
- Plenary Session 6: Immunotherapy and Immunology
Sunday, September 8
- Plenary Session 7: Emerging Therapies and Drug Resistance
- Plenary Session 8: New Strategies for Early Phase Clinical Trials
- Closing Remarks
Opening Plenary Session
5-7 p.m.
CME-Eligible
- Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, Massachusetts
- AACR-St. Baldrick’s Foundation Pediatric Cancer Research Fellowship Awardee Lecture
Alanna J. Church, Boston Children’s Hospital, Boston, Massachusetts
OPENING RECEPTION
7-8:30 p.m.
CONTINENTAL BREAKFAST
7-8 A.M.
plenary Session 1: Cancer Predisposition and the Causes of Cancer
8-10 a.m.
CME-Eligible
- Insights from replication repair deficient cancers on cancer initiation and vulnerability
Uri Y. Tabori, SickKids, Toronto, Ontario, Canada - Genetic predisposition to pediatric cancer: the long way from discovery to surveillance guidelines
Franck Bourdeaut, Institut Curie, Paris, France - Anita Villani, SickKids, Toronto, Ontario, Canada
Short talks selected from proffered abstracts
BREAK
10-10:30 A.M.
Plenary Session 2: Precision Medicine for Pediatric Cancer: Beyond Sequencing
10:30-12:30 p.m.
CME-Eligible
- RNA-based platform as a diagnostic aid for childhood cancer
Adam Shlien, SickKids, Toronto, Ontario, Canada - Integrative proteogenomics for discovery of tumor-specific and neomorphic cancer proteomes
Alex Kentsis, Memorial Sloan Kettering Cancer Center, New York, New York - A federated functional precision initiative for relapsed refractory ALL
Jean-Pierre Bourquin, University Children’s Hospital Zurich, Zürich, Switzerland
Additional speakers to be announced
Lunch Break (lunch on your own)
12:30-2:30 p.m.
Plenary Session 3: Title to Announced
Session organized by the AACR Pediatric Cancer Working Group (PCWG)
2:30-4:30 p.m.
CME-Eligible
Poster Session A
4:30-7 p.m.
CONTINENTAL BREAKFAST
7-8 A.M.
Plenary Session 4: Circulating DNA and Other Novel Early Relapse Detection Tools
8-10 a.m.
CME-Eligible
- Brian D. Crompton, Dana-Farber Cancer Institute, Boston, Massachusetts
- Liquid biopsy for pediatric cancer
Cynthia E. Hawkins, SickKids, Toronto, Ontario, Canada - Opportunities and challenges for liquid biopsies in pediatric oncology
Gudrun Schleiermacher, Institut Curie, Paris, France
Short talks selected from proffered abstracts
BREAK
10-10:30 A.M.
Plenary Session 5: Pediatric Cancer Disparities
10:30 a.m.-12:30 p.m.
CME-Eligible
- Disparities in access to pediatric cancer care
Lena Winestone, University of California San Francisco, San Francisco, California - Disparities in childhood cancer outcomes: Can we move from describing to intervening?
Sumit Gupta, SickKids, Toronto, Ontario, Canada - Title to be announced
Paula Aristizabal, University of California, San Diego, California
LUNCH BREAK (LUNCH ON YOUR OWN)
12:30-2:30 P.M.
Plenary Session 6: Immunotherapy and Immunology
2:30-4:30 p.m
CME-Eligible
- Rayne H. Rouce, Baylor College of Medicine, Houston, Texas
- GD2-specific CAR T cell therapies for pediatric solid cancers
Claudia Rossig, University Children’s Hospital Münster, Muenster, Germany - Mapping microglia: Tumor crosstalk in pediatric brain cancer
Florent Ginhoux, Singapore Immunology Network (SIgN), A*STAR, Biopolis, Singapore
Short talks selected from proffered abstracts
Poster Session B
4:30-7 p.m
CONTINENTAL BREAKFAST
7-8 A.M.
Plenary Session 7: Emerging Therapies and Drug Resistance
8-10 A.M.
CME-Eligible
- Targeting chromatin complexes in cancer
Scott A. Armstrong, Dana-Farber Cancer Institute, Boston, Massachusetts - Olivier Delattre, Institut Curie, Paris, France
- Pathobiology of asparaginase resistance
Alejandro Gutierrez, Boston Children’s Hospital, Boston, Massachusetts
Short talks selected from proffered abstracts
BREAK
10-10:30 A.M.
Plenary Session 8: New Strategies for Early Phase Clinical Trials
10:30 A.m.-12:30 p.m.
CME-Eligible
- How novel clinical research informs pediatric clinical trials
Andrea A. Hayes, Howard University Hospital, Washington, District of Columbia - Trial designs to find early signals of efficacy in rare pediatric cancers
Katherine A. Janeway, Dana-Farber Cancer Institute, Boston, Massachusetts - James H. Doroshow, National Cancer Institute, Bethesda, Maryland
- Gilles Vassal, Gustave Roussy, VIllejuif, France
Closing Remarks
12:30-12:45 p.m.
- Alejandro Gutierrez, Boston Children’s Hospital, Boston, Massachusetts
- Cynthia E. Hawkins, The Hospital for Sick Children, Toronto, Ontario, Canada
- Andrea A. Hayes, Howard University College of Medicine, Washington, DC
- Gilles Vassal, Institut Gustave Roussy, Villejuif, France